Ad
Tuesday, 26 June 2018
Exclusive: BrainStorm will not provide ALS therapy under U.S. Right to Try act
TEL AVIV (Reuters) - BrainStorm Cell Therapeutics Inc will not make its experimental stem cell treatment for neurodegenerative diseases available under the new U.S. "Right to Try" (RTT) act, citing a failure to find a way to enable all patients to afford the treatment.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment